Abstract: The present invention relates to processes for the production of microalgae, cyanobacteria and/or metabolites thereof. Described herein is a process involving, the use of a stimulus applied to a microalgal or cyanobacterial culture to enhance the production of one or more metabolites. Also described herein, is a process for the production of microalgae and/or cyanobacteria comprising an adaptation stage wherein an algal/cyanobacterial culture is grown on a process water feedstock and/or under light emitting diodes (LEDs) emitting light within the spectrum of light wavelengths between around 400 nm and 700 nm, and a production phase, wherein the microalgae or cyanobacteria are grown on the same process water feedstock and/or under the same light conditions used in the adaptation stage. The invention also relates to specific microalgal strains.

Abstract: The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterized by the marker profile CD133?, CD146+, CD34? and CD105+. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.

Abstract: The invention relates to a method for fermenting soy flour in the solid state in order to reduce non-starch polysaccharides and alpha-galactosides, said method comprising the following steps: a) preparation of the fermentation substrate; b) inoculation of the substrate with selected celluloytic bacterial strains; c) incubation; and, optionally, d) drying of the product, which generates a product with: an increase in protein of between 12 and 15% compared to non-fermented soy flour, degradation of the alpha-galactosides of more than 90% compared to non-fermented soy flour, a reduction in non-starch polysaccharides (NSPs) of between 15 and 25%, an amino acid profile similar to that of non-fermented soy flour, and immune-stimulating effects.

Abstract: The present methods involves methods of improving ethanol production which may comprise the addition of clay during ethanol production.

Abstract: A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.

Abstract: The preparation unit comprises a body (2) within which are fixed a first (3) and a second (4) membrane, said first membrane (3) having a first predetermined pore diameter and said second membrane (4) a second predetermined pore diameter smaller than said first predetermined pore diameter of said first membrane (3), said body also comprising means (16, 20) for retrieving said sample collected on said second membrane (4). The method of preparing such a sample comprises the step of procuring such a preparation unit (1), the step of passing a predetermined volume of said liquid through said first membrane and through said second membrane (4) in order to collect a sample on said second membrane (4); and the step of retrieving said sample so collected on said second membrane (4).

Abstract: Aspects of the present disclosure include methods for detecting a low abundance protein and methods for identifying a site of N-glycosylation on a protein. In practicing methods according to certain embodiments, a eukaryotic cell is contacted with an isotopic labeling composition and isotopically labeled N-glycosylated peptides obtained from the eukaryotic cell are assessed by liquid chromatography-tandem mass spectrometry. A predetermined isotopic pattern in the mass spectrum is identified and amino acid sequences of the peptides containing the predetermined isotopic pattern are determined. Systems for identifying a predetermined isotopic pattern in mass spectra and determining amino acid sequences of peptides containing the predetermined isotopic pattern are also described.

Abstract: Methods and kits for detecting the presence of GlcNAc modification of a peptide or protein. The steps of detection may include combining the peptide or protein with PAP35S and a sulfotransferase to produce a reaction product including 35S labeled GlcNAc modified protein or peptide, removing background labeling with a glycosidase, separating the 35S labeled GlcNAc modified protein or peptide from PAP35S, free S-35 sulfate and labeled oligosaccharides if present, and detecting isotopic emissions from the 35S labeled GlcNAc modified peptide or protein. The detection may further include, prior to detection, the step of combining the peptide or protein with a GlcNAc transferase and UDP-GlcNAc under appropriate conditions for the GlcNAc transferase to transfer a GlcNAc to the peptide or protein.

Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

Abstract: The present disclosure relates generally to drug discovery and development and, more particularly, to in vitro assay systems and methods for selecting lead anti-cancer agents for subsequent testing in human and non-human subjects. The present disclosure allows filtering for candidate anti-cancer agents that are not inactivated by liver enzymes, are able to diffuse through cell layers, are not toxic to bone marrow cells, retain anti-cancer activity in the context of stromal support, and are effective after time-limited exposure mimicking non-hepatic clearance by kidneys and other mechanisms.

Abstract: The invention provides a method of diagnosing entry of gastrointestinal contents into the respiratory tract of a patient suffering from reflux disease. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.

Abstract: The present invention provides novel phosphate-solubilizing fungal strains, compositions comprising novel phosphate-solubilizing fungal strains, and methods of using novel phosphate-solubilizing fungal strains to increase the availability of phosphate for plant uptake in soil. In some embodiments, one or more of the novel phosphate-solubilizing fungal strains is coated onto a seed.

Abstract: Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting to an Emergency Department with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity and/or mass in a bodily sample obtained from the patient. Levels of MPO activity or MPO mass in bodily samples from the test subject are then compared to a control value in comparable bodily samples obtained from a control population. Such comparison can also be used to determine the near term treatment of the patient.

Abstract: The present invention relates to methods and compounds for enzyme-mediated amplification of target-associated signals for visualization of biological or chemical targets in samples, wherein the targets are immobilized, in particular the invention relates to the oxidoreductase-mediated signal amplification for visualization of targets in samples comprising cells. The methods of the invention are particular useful for qualitative and quantitative evaluation of biological markers relating to medical diagnostic and therapy.

Abstract: The invention relates to the use of at least one chelating agent, including an iron chelating agent, in order to stimulate the growth of magnetotactic bacteria.

Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.

Abstract: Embodiments of the present invention provide for efficient and economical production and recovery of ethanol or other volatile organic compounds, such as acetic acid, from solid biomass material, particularly on a larger scale, such as on the commercialization or industrial scale. According to one aspect of the invention, the method comprises (a) generating at least about 10 tons of prepared biomass material by adding a microbe, optionally an acid, and optionally, an enzyme to a solid biomass; (b) storing the prepared biomass material for at least about 24 hours in a storage facility to allow production of at least one volatile organic compound from at least a portion of the sugar in the solid biomass; and (c) capturing the at least one volatile organic compound by using a solventless recovery system.

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: The present invention relates to a process for determining mycotoxin production in an interior environment which includes a search for a chemical fingerprint comprising at least one target molecule that is a VOC, optionally cyclic, associated with mycotoxin production, preferably selected from the group comprising cububene, cadiene, copaene, ylangene, D germacrene, muurolane, 1,1-dimethylbutylbenzene, 1,1,2-trimethyl-propyl-benzene, 1-hexyltetradecylbenzene, tetratetracontane, 1-ethyldecylbenzene, hydroxytoluene butylate, 1-butyloctylbenzene, 1-propylnonylbenzene, 2-methylisoborneol and at least one sesquiterpene.

Abstract: A method for analyzing blood cells includes: preparing a measurement specimen for classifying white blood cells, by mixing a sample with a reagent in order to hemolyze red blood cells contained in the sample and to fluorescently stain nucleic acid in white blood cells contained in the sample; detecting, by flowing the prepared measurement specimen in a flow cell, fluorescence emitted from each blood cell in the measurement specimen and two types of scattered light at respective different angles, and obtaining a fluorescence signal and two types of scattered light signals; and classifying the white blood cells into at least four groups and detecting neoplastic lymphocytes, by performing analysis using at least three types of parameters based on the obtained fluorescence signal and two types of scattered light signals.